about
Novel therapeutic targets in Helicobacter pylori.'Rescue' therapies for the management of Helicobacter pylori infection.Helicobacter pylori and pregnancy-related disorders.Clinical practice: diagnosis and evaluation of dyspepsia.Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile.Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapyOrally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infectionShort-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.Antibiotics resistance of Helicobacter pylori and treatment modalities in children with H. pylori infection.Nontraditional therapies to treat Helicobacter pylori infection.Progress in genetic engineering of peanut (Arachis hypogaea L.)--a review.Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori.Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate.Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori.Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B.
P2860
Q33195402-539DBCA6-A7C9-4830-AA8F-E3FD355D17CEQ33371187-8603009F-C768-4E5F-ABC4-C777E404E366Q33413540-2A20E4A6-9EF5-4D34-BB15-A011FC255206Q33687928-BBABC1CC-AADE-4EC2-A5E7-15A346076E92Q33727000-D47E2489-1D6D-4FCD-A0BF-9234E7377F75Q34175742-3AC368EA-E683-4E3C-A44E-648132C50E0EQ34224762-1746DE0D-FFCF-48A6-9353-2DD44D89B2F4Q34722715-DF674186-7A13-48A4-9643-4B44458A38ABQ34941937-5FB08BBF-8C41-4167-9EFB-21F75D466458Q37394555-CB4C3766-54E3-4F6B-A5F3-C0784914CFDDQ37663186-051A5334-A64E-48C5-B07A-B2F83A192751Q38200572-FB32F61C-A85B-4C5E-944F-46A40D709BA0Q38334401-3A3F2947-4BCA-40CE-8DA2-A5F4375F1811Q44535163-8373FDA1-47D5-4149-BDED-E42A1A1A3412Q44700551-00900EED-F885-4A23-9E03-F9A097B50165Q46110162-53490B5F-727E-4097-BB09-8F873D4B78C9Q47768949-0802B362-2684-49CE-9A54-2E423F0C9E7A
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Helicobacter pylori: the challenge in therapy.
@ast
Helicobacter pylori: the challenge in therapy.
@en
Helicobacter pylori: the challenge in therapy.
@nl
type
label
Helicobacter pylori: the challenge in therapy.
@ast
Helicobacter pylori: the challenge in therapy.
@en
Helicobacter pylori: the challenge in therapy.
@nl
prefLabel
Helicobacter pylori: the challenge in therapy.
@ast
Helicobacter pylori: the challenge in therapy.
@en
Helicobacter pylori: the challenge in therapy.
@nl
P2093
P2860
P1433
P1476
Helicobacter pylori: the challenge in therapy.
@en
P2093
Franco Bazzoli
Paolo Pozzato
Theodore Rokkas
P2860
P356
10.1046/J.1523-5378.7.S1.7.X
P478
P577
2002-01-01T00:00:00Z